Great commentary people on the latest announcement.I think one...

Great commentary people on the latest announcement.

I think one of the biggest problems tMC has had in the past has been it's strategic timing.
That is obviously very costly.
That is one problem I would expect and hope that Gary Jacobs would fix and get it right given the potential of Immuron has been staring us in the face for so long.

“This is an important strategic initiative towards enhancing commercialization of theTravelan®/IMM-124E franchise,” said Dr. Gary S. Jacob, CEO of Immuron Limited. “It is importantto note that Travelan® and IMM-124E, our drug candidate presently in clinical development in gutmediated diseases, are one and the same. We believe seeking FDA registration for IMM-124E as adrug to prevent travelers’ diarrhea offers the potential for substantial sales benefits to Immuron.We are moving aggressively forward to develop IMM-124E through the FDA by planning to file anInvestigational New Drug (IND) application for prevention of travelers’ diarrhea, and pursuing withFDA a rapid path for its clinical development.”